Literature DB >> 26966861

Effects of transgene expression level per cell in mice livers on induction of transgene-specific immune responses after hydrodynamic gene transfer.

Y Yin1, Y Takahashi1, A Hamana1, M Nishikawa1, Y Takakura1.   

Abstract

We previously showed that high and sustained transgene expression of antigenic proteins induced transgene-specific immune responses. In the present study, a detailed relationship between the level of transgene expression per cell and immune response after hydrodynamic gene transfer was investigated. Cypridina luciferase (cLuc), a secretory antigenic reporter protein, was selected as a model antigen, and pROSA-cLuc, a plasmid expressing cLuc, was constructed. A fixed dose (30 μg) of pROSA-cLuc was delivered to mice by a single hydrodynamic injection or three injections at 24-h intervals because the number of cells transfected with plasmids is dependent on the number of hydrodynamic injections. Serum cLuc activity, an indicator of the total amount of cLuc transgene expression, was almost equal between these two groups. In contrast, the high-dose single injection induced higher levels of cLuc-specific humoral and cellular immune responses than the three low-dose injections. Moreover, the serum cLuc activity of the high-dose single injection group began to decline ~10 days after injection, whereas the activity remained constant in the three low-dose injection group. These results indicate that it is preferable to reduce the level of transgene expression per cell to avoid induction of the transgene-specific immune response after hydrodynamic gene transfer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26966861     DOI: 10.1038/gt.2016.26

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  18 in total

1.  Purification and molecular weight of Cypridina luciferase.

Authors:  F I TSUJI; R SOWINSKI
Journal:  J Cell Comp Physiol       Date:  1961-10

2.  Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression.

Authors:  Naoki Kobayashi; Yumi Matsui; Atsushi Kawase; Kazuhiro Hirata; Makoto Miyagishi; Kazunari Taira; Makiya Nishikawa; Yoshinobu Takakura
Journal:  J Pharmacol Exp Ther       Date:  2003-11-10       Impact factor: 4.030

3.  Rapid methods of detecting the target molecule in immunohistology using a bioluminescence probe.

Authors:  Chun Wu; Ke-Yong Wang; Xin Guo; Masanori Sato; Michitaka Ozaki; Shyohei Shimajiri; Yoshihiro Ohmiya; Yasuyuki Sasaguri
Journal:  Luminescence       Date:  2012-03-08       Impact factor: 2.464

Review 4.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

Review 5.  Gene therapy clinical trials worldwide to 2007--an update.

Authors:  Michael L Edelstein; Mohammad R Abedi; Jo Wixon
Journal:  J Gene Med       Date:  2007-10       Impact factor: 4.565

6.  Effect of tissue-specific promoters and microRNA recognition elements on stability of transgene expression after hydrodynamic naked plasmid DNA delivery.

Authors:  Lisa J Wolff; Jon A Wolff; Magdolna G Sebestyén
Journal:  Hum Gene Ther       Date:  2009-04       Impact factor: 5.695

7.  Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival.

Authors:  P Bertolino; M C Trescol-Biémont; C Rabourdin-Combe
Journal:  Eur J Immunol       Date:  1998-01       Impact factor: 5.532

8.  Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.

Authors:  T-P Zhang; D-Y Jin; R M Wardrop; T Gui; R Maile; J A Frelinger; D W Stafford; P E Monahan
Journal:  Gene Ther       Date:  2006-10-26       Impact factor: 5.250

Review 9.  Pathways of antigen processing.

Authors:  Janice S Blum; Pamela A Wearsch; Peter Cresswell
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

Review 10.  Review--the use of immunosuppressive agents to prevent neutralizing antibodies against a transgene product.

Authors:  M A Potter; P L Chang
Journal:  Ann N Y Acad Sci       Date:  1999-06-18       Impact factor: 5.691

View more
  1 in total

1.  Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.

Authors:  Taran S Lundgren; Gabriela Denning; Sean R Stowell; H Trent Spencer; Christopher B Doering
Journal:  Blood Adv       Date:  2022-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.